TEVA-TIAPROFENIC ACID 200 MG — DIN 02179679
TIAPROFENIC ACID : 200 MG · TEVA CANADA LIMITED · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is TEVA-TIAPROFENIC ACID?
TEVA-TIAPROFENIC ACID 200 MG contains TIAPROFENIC ACID : 200 MG. It is listed in the Health Canada Drug Product Database under DIN 02179679, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 01-Jun-2011. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-TIAPROFENIC ACID used for?
TEVA – TIAPROFENIC ACID (Tiaprofenic acid) is indicated for: the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis (degenerative joint disease). Use of TEVA – TIAPROFENIC ACID should be limited to the lowest effective dose for the shortest possible duration of treatment in order to minimize the potential risk for cardiovascular or gastrointestinal adverse events.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Tiaprofenic Acid in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
11 holders have a Canadian DIN containing Tiaprofenic Acid, across 25 DINs, of which 2 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| TEVA CANADA LIMITED | 2 | 2 | TEVA-TIAPROFENIC ACID | Sourceable in Canada |
| AVENTIS PHARMA INC | 3 | 0 | ALBERT TIAFEN SR, ALBERT TIAFEN TAB 200MG, ALBERT TIAFEN TAB 300MG | No marketed DIN |
| HOECHST ROUSSEL CANADA INC. | 3 | 0 | SURGAM SR CAP 300MG, SURGAM TAB 200MG, SURGAM TAB 300MG | No marketed DIN |
| ROUSSEL CANADA INC. | 3 | 0 | SURGAM TAB 200MG, SURGAM TAB 300MG, SURGAM-SR SRC 300MG | No marketed DIN |
| APOTEX INC | 2 | 0 | APO-TIAPROFENIC TABLETS -300MG, APO-TIAPROFENIC TABLETS-200MG | No marketed DIN |
| DOMINION PHARMACAL | 2 | 0 | DOM-TIAPROFENIC | No marketed DIN |
| NU-PHARM INC | 2 | 0 | NU-TIAPROFENIC - TAB 200MG, NU-TIAPROFENIC - TAB 300MG | No marketed DIN |
| PENTAPHARM LTD. | 2 | 0 | PENTA-TIAPROFENIC TABLETS | No marketed DIN |
| PHARMASCIENCE INC | 2 | 0 | PMS-TIAPROFENIC | No marketed DIN |
| PRO DOC LIMITEE | 2 | 0 | TIAPROFENIC-200 - TAB, TIAPROFENIC-300 - TAB | No marketed DIN |
| SANOFI-AVENTIS CANADA INC | 2 | 0 | SURGAM, SURGAM SR | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 200 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | bottles of 100, 500, 1000 and unit dose boxes of 100. |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Tiaprofenic Acid |
|---|---|
| ATC code | M01AE11 |
| AHFS class | 28:08.04.92 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02179679 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2179679 |
| Brand name | TEVA-TIAPROFENIC ACID |
| Generic / active ingredient | TIAPROFENIC ACID : 200 MG |
| Market authorization holder | TEVA CANADA LIMITED |
| Health Canada schedule | Prescription |
| ATC code | M01AE11 |
| ATC anatomical main group | M — Musculo-skeletal system |
| ATC therapeutic subgroup | M01AE |
| Current status | MARKETED |
| Status date | 01-Jun-2011 |
| Original market date | 1996-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 25 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| TEVA-TIAPROFENIC ACID | 300 MG | TABLET | TEVA CANADA LIMITED | MARKETED | 02179687 |
| ALBERT TIAFEN SR | 300 MG | CAPSULE (SUSTAINED-RELEASE) | AVENTIS PHARMA INC | CANCELLED PRE MARKET | 02152576 |
| ALBERT TIAFEN TAB 200MG | 200 MG | TABLET | AVENTIS PHARMA INC | CANCELLED POST MARKET | 01924613 |
| ALBERT TIAFEN TAB 300MG | 300 MG | TABLET | AVENTIS PHARMA INC | CANCELLED POST MARKET | 01924621 |
| APO-TIAPROFENIC TABLETS -300MG | 300 MG | TABLET | APOTEX INC | CANCELLED POST MARKET | 02136120 |
| APO-TIAPROFENIC TABLETS-200MG | 200 MG | TABLET | APOTEX INC | CANCELLED POST MARKET | 02136112 |
| DOM-TIAPROFENIC | 300 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | 02231060 |
| DOM-TIAPROFENIC | 200 MG | TABLET | DOMINION PHARMACAL | CANCELLED PRE MARKET | 02231059 |
| NU-TIAPROFENIC - TAB 200MG | 200 MG | TABLET | NU-PHARM INC | CANCELLED POST MARKET | 02146878 |
| NU-TIAPROFENIC - TAB 300MG | 300 MG | TABLET | NU-PHARM INC | CANCELLED POST MARKET | 02146886 |
2 · Same class — other molecules in ATC M01AE
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Ibuprofen | ACTIPROFEN - CAPLET 200MG · ADVIL 12 HOUR · ADVIL ARTHRITIS PAIN · ADVIL CAPLETS · +107 more | 143 | 46 | Yes |
| Naproxen | ALEVE BACK AND BODY PAIN · ALEVE CAPLETS · ALEVE LIQUID GELS · ALEVE NIGHTTIME · +81 more | 125 | 31 | Yes |
| Ibuprofen, Combinations | ADVIL COLD & FLU · ADVIL COLD & SINUS CONVENIENCE PACK · ADVIL COLD & SINUS EXTRA STRENGTH LIQUI-GELS · ADVIL COLD & SINUS LIQUI-GELS · +36 more | 40 | 13 | Yes |
| Naproxen And Esomeprazole | MYLAN-NAPROXEN/ESOMEPRAZOLE MR · VIMOVO | 4 | 4 | Yes |
| Ketoprofen | KETOPROFEN · KETOPROFEN SR · KETOPROFEN SUPPOSITORIES · KETOPROFEN-E · +28 more | 36 | 3 | Yes |
| Tiaprofenic Acid | ALBERT TIAFEN SR · ALBERT TIAFEN TAB 200MG · ALBERT TIAFEN TAB 300MG · APO-TIAPROFENIC TABLETS -300MG · +15 more | 25 | 2 | Yes |
| Flurbiprofen | ANSAID TABLETS 100 MG · ANSAID TABLETS 50 MG · FLURBIPROFEN · FLURBIPROFEN-100 TAB 100MG · +12 more | 19 | 2 | Yes |
| Oxaprozin | APO-OXAPROZIN · DAYPRO · RHOXAL-OXAPROZIN | 3 | 0 | Not in Canada |
| Fenoprofen | NALFON CAP 300MG · NALFON TAB 600MG | 2 | 0 | Not in Canada |
| Naproxen And Diphenhydramine | PAIN RELIEVER & SLEEP AID | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC M01A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| M01AB | Diclofenac · Diclofenac, Combinations · Etodolac · Indometacin · Ketorolac · +2 more | 170 | 38 |
| M01AH | Celecoxib · Rofecoxib | 72 | 30 |
| M01AC | Meloxicam · Piroxicam · Tenoxicam | 67 | 14 |
| M01AG | Mefenamic Acid | 7 | 1 |
| M01AX | Nabumetone | 12 | 1 |
| M01AA | Oxyphenbutazone · Phenylbutazone · Phenylbutazone, Combinations | 7 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.